It is not selling better than Dendreon because both charge $90,000 per patient. If Europe approves they will not pay more than $28,000. Then how does it charge the U.S. $90,000. under Obamacare cutbacks.
It's not as bad as it looks, MDVN shareholders have enough money to cover the 90,000 a year when they get diagnosed.
If i didn't know any better I would say MDVN is giving shareholders cancer on purpose so they can become their new prime client. Gotta admire the heroic efforts of those noble "scientists"over there
A couple of old Dendreonites crying in their beers. In fact, Provenge in no way competes with Xtandi. I'd be happy to see a lot of these patients get Provenge as the first line of treatment for relapsed pc, but it's not happening yet.